Identify, control, and prevent
Assays

Identify, control, and prevent the spread of CPO

The BD MAX™ Check-Points CPO assay provides direct detection of carbapenemase-
producing organisms (CPO) for improved patient management and infection control

Challenge of carbapenem resistance
Effective screening controls the spread
Improving screening efficiency
  • The European CDC states that pathogens resistant to carbapenems are one of the biggest threats to patient safety1
  • A large proportion of carbapenem-resistant Enterobacteriaceae (CRE) infections currently lack effective and relatively safe antibiotic treatment options10
  • CRE patients are 3 times more likely to receive inappropriate empiric therapy than non-CRE patients (46.5% vs 11.8%) resulting in longer hospital stays and increased system cost2
  • Carbapenemase genes KPC and OXA-48 were found most frequently in carbapenemase resistant Klebsiella pneumoniae and Escherichia coli3
Screening for colonisation is a key component of CPO control4
<strong>Screening for colonisation is a key component of CPO control<sup>4</sup></strong>
Icon 1
Active surveillance can reduce transmission of CPO in healthcare settings5,6
Icon 1
Screening hospital inpatients for CPO can be cost-effective and even cost-saving6
Icon 1
Hospitals in the Netherlands and UK have estimated the economic impact of an out-break in their facilities to be approximately €1,000,0007,8
The European Centre for Disease Prevention and Control recommends investing while prevalence is low, as once an endemic situation is reached, it is more costly and less effective9

BD MAX™ Check-Points CPO assay is an integrated molecular screening solution

  • Provides results for the five most common carbapenemase genes in Gram-negative bacteria
  • Test can be processed from rectal swabs
KPC
OXA-48*
NDM
VIM/IMP
* OXA-48 and OXA-48 like
  • Results in <2.5 hours compared to culture which can take up to 48 hours
  • Fully integrated on the BD MAX™ System, a fully automated molecular system capable of running BD and partner developed assays as well as laboratory-developed tests
Improved patient<br />
management
Improved patient
management
Workflow<br />
efficiency
Workflow
efficiency
Fast screening<br />
results
Fast screening
results